About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker KYNB · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Aug 17, 2026A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498 · Metastatic Castration-Resistant Prostate Cancer
FG-3246
KYNB
Kyntra Bio
Phase 2Recruiting75Mar 31, 2028Registry ↗
Jul 23, 2026A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Parti…
NCT07722988 · Myelodysplastic Syndromes
Roxadustat, Placebo
KYNB
Kyntra Bio
Phase 3Not yet recruiting201Sep 2030Registry ↗
Nov 5, 2024Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Che…
NCT03941093 · Pancreatic Cancer Non-resectable
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab +…
KYNB
Kyntra Bio
Phase 3Completed284Jun 11, 2024Registry ↗
Sep 19, 2024Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmon…
NCT03955146 · Idiopathic Pulmonary Fibrosis
Pamrevlumab, Placebo
KYNB
Kyntra Bio
Phase 3Terminated393Mar 20, 2023Registry ↗
Aug 27, 2024Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DM…
NCT02606136 · Duchenne Muscular Dystrophy
Pamrevlumab
KYNB
Kyntra Bio
Phase 2Terminated21May 7, 2020Registry ↗
Aug 26, 2024Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participant…
NCT04632940 · Duchenne Muscular Dystrophy
Pamrevlumab, Placebo
KYNB
Kyntra Bio
Phase 3Terminated73Jun 12, 2023Registry ↗
Aug 12, 2024Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fib…
NCT04419558 · Idiopathic Pulmonary Fibrosis
Pamrevlumab, Placebo
KYNB
Kyntra Bio
Phase 3Terminated372Sep 4, 2023Registry ↗
Aug 1, 2024Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysp…
NCT03263091 · Primary MDS (Very Low, Low or Intermediate IPSS-R With <5%…
Roxadustat, Placebo
KYNB
Kyntra Bio
Phase 3Terminated184Mar 9, 2023Registry ↗
Mar 12, 2024Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambu…
NCT04371666 · Duchenne Muscular Dystrophy
Pamrevlumab, Placebo
KYNB
Kyntra Bio
Phase 3Terminated98Feb 13, 2023Registry ↗
Jul 12, 2023Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
NCT00074698 · Idiopathic Pulmonary Fibrosis
FG-3019
KYNB
Kyntra Bio
Phase 1Completed21—Registry ↗
Jun 6, 2023A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participan…
NCT05301517 · Chemotherapy Induced Anemia
SEPO®, Roxadustat
KYNB
Kyntra Bio
Phase 3Completed159Apr 3, 2023Registry ↗
May 3, 2023Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplas…
NCT03303066 · Anemia, Myelodysplastic Syndrome
FG-4592, Placebo
KYNB
Kyntra Bio
Phase 2/3Completed43Jan 11, 2023Registry ↗
Mar 2, 2023A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Adv…
NCT02210559 · Pancreatic Cancer (Unresectable)
FG-3019, Gemcitabine
KYNB
Kyntra Bio
Phase 1/2Completed37Dec 15, 2021Registry ↗
Sep 13, 2022Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (E…
NCT04410198 · Anemia Associated With End Stage Renal Disease (ESRD)
Roxadustat
KYNB
Kyntra Bio
Phase 3Completed203Jun 30, 2021Registry ↗
Jul 26, 2022Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment…
NCT04484857 · Anemia Associated With End Stage Renal Disease
Roxadustat
KYNB
Kyntra Bio
Phase 3Completed283Jul 9, 2021Registry ↗
Jul 18, 2022Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acut…
NCT04432298 · COVID-19
Pamrevlumab, Placebo
KYNB
Kyntra Bio
Phase 2Terminated22Mar 22, 2021Registry ↗
Jul 5, 2022Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediat…
NCT04621331 · Anemia Associated With Chronic Kidney Disease
Roxadustat
KYNB
Kyntra Bio
Phase 3Withdrawn0May 23, 2022Registry ↗
Jun 3, 2022Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
NCT04076943 · Chemotherapy Induced Anemia
Roxadustat
KYNB
Kyntra Bio
Phase 2Completed92Mar 26, 2021Registry ↗
May 6, 2022Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia…
NCT04059913 · CKD Anemia in Dialysis Participants
Roxadustat
KYNB
Kyntra Bio
Phase 4Completed318Nov 19, 2021Registry ↗
Feb 10, 2022Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
NCT01244763 · Chronic Kidney Disease, Anemia
Roxadustat
KYNB
Kyntra Bio
Phase 2Completed145Jun 13, 2012Registry ↗
Jan 11, 2022Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance He…
NCT01147666 · End Stage Renal Disease, Anemia
Roxadustat, Epoetin Alfa
KYNB
Kyntra Bio
Phase 2Completed161Oct 15, 2012Registry ↗
Nov 19, 2021Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Di…
NCT00761657 · Chronic Kidney Disease, Anemia
Roxadustat, Placebo
KYNB
Kyntra Bio
Phase 2Completed117Jun 21, 2010Registry ↗
Oct 29, 2021Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants…
NCT02273726 · CKD Anemia in Stable Dialysis Patients
Epoetin Alfa, Roxadustat
KYNB
Kyntra Bio
Phase 3Completed741Sep 19, 2018Registry ↗
Oct 1, 2021Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Di…
NCT02052310 · Anemia in Incident Dialysis Patients
Roxadustat, Epoetin Alfa
KYNB
Kyntra Bio
Phase 3Completed1,043Sep 21, 2018Registry ↗
Oct 1, 2021A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and N…
NCT01750190 · CKD Anemia
Roxadustat, Placebo
KYNB
Kyntra Bio
Phase 3Completed922Sep 24, 2018Registry ↗
Oct 1, 2021Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With…
NCT01630889 · Chronic Kidney Disease, End Stage Renal Disease
Roxadustat
KYNB
Kyntra Bio
Phase 2Completed15Dec 12, 2019Registry ↗
Oct 1, 2021Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Ery…
NCT01414075 · Dialysis, Anemia
Roxadustat, Oral Iron
KYNB
Kyntra Bio
Phase 2Completed60Jan 10, 2013Registry ↗
Sep 4, 2020Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary…
NCT01890265 · Idiopathic Pulmonary Fibrosis
Pamrevlumab, Placebo
KYNB
Kyntra Bio
Phase 2Completed160Nov 16, 2017Registry ↗
Oct 9, 2019Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
NCT01262001 · Idiopathic Pulmonary Fibrosis
FG-3019, FG-3019
KYNB
Kyntra Bio
Phase 2Completed90Jun 26, 2014Registry ↗
Aug 2, 2019Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropat…
NCT00754143 · Diabetes Mellitus, Diabetic Nephropathy
FG-3019, FG-3019
KYNB
Kyntra Bio
Phase 1Completed38Dec 2009Registry ↗
Jul 31, 2019Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomeruloscle…
NCT00782561 · Focal Segmental Glomerulosclerosis
FG-3019
KYNB
Kyntra Bio
Phase 1Terminated2Jun 18, 2009Registry ↗
Feb 22, 2019Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi an…
NCT00913393 · Type 2 Diabetes Mellitus, Diabetic Nephropathy
FG-3019, FG-3019
KYNB
Kyntra Bio
Phase 2Terminated46Jun 2010Registry ↗
Aug 24, 2017FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
NCT02652819 · Anemia
FG-4592, Placebo
KYNB
Kyntra Bio
Phase 3Completed154Jan 24, 2017Registry ↗
Aug 24, 2017FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
NCT02652806 · Anemia
FG-4592, Epoetin Alfa
KYNB
Kyntra Bio
Phase 3Completed305Jan 24, 2017Registry ↗
Aug 16, 2016A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
NCT01217632 · Liver Fibrosis Due to Chronic Hepatitis B Infection
FG-3019, Placebo
KYNB
Kyntra Bio
Phase 2Terminated114Jun 2015Registry ↗

35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:28 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances